The Myelin Repair Foundation (MRF) is partnering with the National Institutes of Health (NIH) to conduct a clinical trial on a potential therapeutic that may protect and repair myelin in multiple sclerosis (MS) patients. MRF investigators found that this therapeutic—an FDA-approved drug to treat hypertension—may be neuroprotective. That is, unlike current MS therapies which all suppress the immune system, MRF-008 may help protect myelin-producing cells (oligodendrocytes) in the brain from damage. The MRF-008 clinical trial represents a game-changing opportunity for the MRF and its supporters to help develop next-generation MS therapeutics. Instead of targeting the immune system, such therapeutics will protect and repair myelin—with the potential to transform the lives of MS patients around the world.
Posted on: Wed, 29 Jan 2014 16:57:08 +0000
Trending Topics
Recently Viewed Topics
© 2015